Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Early Phase 1

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 1(4)

Early Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01411267Phase 1Completed

AC220 for Children With Relapsed/Refractory ALL or AML

Role: collaborator

NCT03845881Early Phase 1Completed

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

Role: collaborator

NCT01565668Phase 2Completed

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT01468467Phase 1Completed

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Role: collaborator

NCT01390337Phase 1Completed

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Role: collaborator

NCT00979173Phase 1Completed

Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

Role: collaborator

All 6 trials loaded